DIA Europe 2019 has ended
Back To Schedule
Wednesday, February 6 • 10:15 - 10:45
#PS04: Oral Poster Session 4 - Regulatory Science & Value and Access Content Hub

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session


An overview of the current status and trends in the Breakthrough Designation, PRIME and SAKIGAKE expedited review programs
Pedro Borga, MPharm

Early Actions granted by FDA: a review of the frequency and importance of NDA/BLA approvals in advance of DUFA action date
Camille Metais, MSc


Camille Metais

Senior Director Regulatory Affairs, Alexion Pharma GmbH
avatar for Pedro Borga

Pedro Borga

Consultant, Lifescience Dynamics Ltd

Wednesday February 6, 2019 10:15 - 10:45 CET
Content Hub 4 Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria